Wyss In­sti­tute spin­out looks to re­vamp drug de­vel­op­ment for CNS dis­eases — with CRISPR tad­poles

For Rett syn­drome, like oth­er neu­ro­log­i­cal dis­eases, drug de­vel­op­ment has large­ly been a sto­ry of fail­ure.

To Richard No­vak, a for­mer lead en­gi­neer at the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER